BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23880303)

  • 21. Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma.
    Lim SM; Kim HR; Shim HS; Soo RA; Cho BC
    Future Oncol; 2013 Mar; 9(3):377-86. PubMed ID: 23469973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small molecule inhibition of fibroblast growth factor receptors in cancer.
    Liang G; Chen G; Wei X; Zhao Y; Li X
    Cytokine Growth Factor Rev; 2013 Oct; 24(5):467-75. PubMed ID: 23830577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand.
    Anderson J; Burns HD; Enriquez-Harris P; Wilkie AO; Heath JK
    Hum Mol Genet; 1998 Sep; 7(9):1475-83. PubMed ID: 9700203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. De-regulated FGF receptors as therapeutic targets in cancer.
    Knights V; Cook SJ
    Pharmacol Ther; 2010 Jan; 125(1):105-17. PubMed ID: 19874848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Future applications of FGF/FGFR inhibitors in cancer.
    Ghedini GC; Ronca R; Presta M; Giacomini A
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):861-872. PubMed ID: 29936878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FGF receptor mutations: dimerization syndromes, cell growth suppression, and animal models.
    Kannan K; Givol D
    IUBMB Life; 2000 Mar; 49(3):197-205. PubMed ID: 10868910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Responsiveness of developing dental tissues to fibroblast growth factors: expression of splicing alternatives of FGFR1, -2, -3, and of FGFR4; and stimulation of cell proliferation by FGF-2, -4, -8, and -9.
    Kettunen P; Karavanova I; Thesleff I
    Dev Genet; 1998; 22(4):374-85. PubMed ID: 9664689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances and challenges in targeting FGFR signalling in cancer.
    Babina IS; Turner NC
    Nat Rev Cancer; 2017 May; 17(5):318-332. PubMed ID: 28303906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3) in the developing head and face.
    Wilke TA; Gubbels S; Schwartz J; Richman JM
    Dev Dyn; 1997 Sep; 210(1):41-52. PubMed ID: 9286594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.
    André F; Cortés J
    Breast Cancer Res Treat; 2015 Feb; 150(1):1-8. PubMed ID: 25677745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting mutant fibroblast growth factor receptors in cancer.
    Greulich H; Pollock PM
    Trends Mol Med; 2011 May; 17(5):283-92. PubMed ID: 21367659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A rare premalignant prostate tumor epithelial cell syndecan-1 forms a fibroblast growth factor-binding complex with progression-promoting ectopic fibroblast growth factor receptor 1.
    Wu X; Kan M; Wang F; Jin C; Yu C; McKeehan WL
    Cancer Res; 2001 Jul; 61(13):5295-302. PubMed ID: 11431373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.
    Dieci MV; Arnedos M; Andre F; Soria JC
    Cancer Discov; 2013 Mar; 3(3):264-79. PubMed ID: 23418312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting FGFR Signaling in Cancer.
    Touat M; Ileana E; Postel-Vinay S; André F; Soria JC
    Clin Cancer Res; 2015 Jun; 21(12):2684-94. PubMed ID: 26078430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
    Repetto M; Crimini E; Giugliano F; Morganti S; Belli C; Curigliano G
    Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1233-1252. PubMed ID: 34591728
    [No Abstract]   [Full Text] [Related]  

  • 36. Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer.
    Zammit C; Barnard R; Gomm J; Coope R; Shousha S; Coombes C; Johnston C
    J Pathol; 2001 May; 194(1):27-34. PubMed ID: 11329138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer.
    Brooks AN; Kilgour E; Smith PD
    Clin Cancer Res; 2012 Apr; 18(7):1855-62. PubMed ID: 22388515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different abilities of the four FGFRs to mediate FGF-1 translocation are linked to differences in the receptor C-terminal tail.
    Sørensen V; Wiedlocha A; Haugsten EM; Khnykin D; Wesche J; Olsnes S
    J Cell Sci; 2006 Oct; 119(Pt 20):4332-41. PubMed ID: 17003104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential expression of fibroblast growth factor receptors 1 to 4 and ligand genes in late fetal and early postnatal rat lung.
    Powell PP; Wang CC; Horinouchi H; Shepherd K; Jacobson M; Lipson M; Jones R
    Am J Respir Cell Mol Biol; 1998 Oct; 19(4):563-72. PubMed ID: 9761752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes.
    Bellus GA; Gaudenz K; Zackai EH; Clarke LA; Szabo J; Francomano CA; Muenke M
    Nat Genet; 1996 Oct; 14(2):174-6. PubMed ID: 8841188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.